Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History IMAB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics IMAB

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

I-Mab

IMAB
Current price
2.05 USD -0.25 USD (-10.87%)
Last closed 2.31 USD
ISIN US44975P1030
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 175 569 664 USD
Yield for 12 month +29.75 %
1Y
3Y
5Y
10Y
15Y
IMAB
21.11.2021 - 28.11.2021

I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland. Address: 2440 Research Boulevard, Rockville, MD, United States, 20850

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

5.60 USD

P/E Ratio

Dividend Yield

Financials IMAB

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures IMAB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

Last Year

+27 644 000 USD

Current Quarter

Last Quarter

Current Year

Last Year

+27 644 000 USD

Current Quarter

Last Quarter

EBITDA -47 981 500 USD
Operating Margin TTM
Price to Earnings
Return On Assets TTM -11.05 %
PEG Ratio
Return On Equity TTM -19.70 %
Wall Street Target Price 5.60 USD
Revenue TTM 3 492 091 USD
Book Value 2.43 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -62.10 %
Dividend Yield
Gross Profit TTM 41 594 000 USD
Earnings per share -0.55 USD
Diluted Eps TTM -0.55 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation IMAB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 0.99
Price Sales TTM 25.39
Enterprise Value EBITDA 0.14
Price Book MRQ 0.89

Technical Indicators IMAB

For 52 Weeks

0.60 USD 3.08 USD
50 Day MA 1.59 USD
Shares Short Prior Month 271 800
200 Day MA 1.16 USD
Short Ratio 0.46
Shares Short 379 058
Short Percent 0.65 %